Welcome to our dedicated page for Aldeyra Therapeu news (Ticker: ALDX), a resource for investors and traders seeking the latest updates and insights on Aldeyra Therapeu stock.
Aldeyra Therapeutics (ALDX) is a clinical-stage biotechnology company developing innovative therapies targeting diseases mediated by toxic aldehydes, with active programs in ocular inflammation and systemic immune disorders. This page provides investors and industry professionals with comprehensive access to Aldeyra's official announcements, including clinical trial updates, regulatory milestones, and strategic partnerships.
Key resources include real-time updates on product candidates like reproxalap for dry eye disease, filings with regulatory agencies, and research collaborations. Users gain a centralized hub to track the company's progress in addressing conditions such as noninfectious anterior uveitis and metabolic disorders through its novel aldehyde sequestration platform.
Regular updates cover Phase clinical results, FDA communications, intellectual property developments, and scientific presentations. The curated news feed enables efficient monitoring of Aldeyra's pipeline advancements and market positioning within the precision medicine landscape.
Bookmark this page for direct access to verified ALDX disclosures and analysis essential for evaluating the company's therapeutic innovations and investment potential.
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced that Todd C. Brady, M.D., Ph.D., President and CEO, will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, at 3:40 p.m. ET. A live webcast of the presentation will be available on their investor relations page, and it will remain archived for 90 days. Aldeyra is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases, with investigational compounds like reproxalap and ADX-629 targeting reactive aldehyde species.
Aldeyra Therapeutics (Nasdaq: ALDX) has finalized the Phase 3 TRANQUILITY Trial design for its 0.25% reproxalap ophthalmic solution aimed at treating dry eye disease. The primary endpoint is ocular redness improvement over 90 minutes in a dry eye chamber, with approximately 150 patients per arm. Results from the run-in cohort indicated a significant decline in tear RASP levels after reproxalap administration, confirming its mechanism of action. The TRANQUILITY and TRANQUILITY-2 trials are expected to begin in H1 2021, with results anticipated in the second half of the year.
Aldeyra Therapeutics (Nasdaq: ALDX) announced the closing of its public offering of 7,868,421 common stock shares at a price of $9.50 each, raising approximately $74.7 million in gross proceeds. The shares included 1,026,315 sold due to underwriters' exercised options. Funds will be used for the development of reproxalap, other product candidates, and general corporate purposes. Jefferies LLC and SVB Leerink LLC managed the offering. The offering was registered under a shelf registration statement with the SEC.
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) has announced an underwritten public offering of 6,842,106 shares at $9.50 each, aiming for approximately $65.0 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase an additional 1,026,315 shares. Proceeds will support the development of Aldeyra's lead compound, reproxalap, alongside other candidates and general corporate needs. The transaction is expected to close by January 19, 2021, pending customary conditions.
Aldeyra Therapeutics (Nasdaq: ALDX) announced a proposed public offering of its common stock, with underwriters receiving a 30-day option to purchase an additional 15%. The offering aims to raise funds for the development of Aldeyra's lead compound reproxalap, among other product candidates, as well as for working capital and corporate purposes. All shares will be sold by Aldeyra under a previously filed shelf registration statement. Jefferies LLC and SVB Leerink LLC are the joint book-running managers for this offering.
Aldeyra Therapeutics (Nasdaq: ALDX) announced that CEO Todd C. Brady will participate in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference. The chat is scheduled for January 11, 2021, at 6:00 a.m. ET, and will be accessible on the company's website. This event will be archived for 90 days. Aldeyra is a clinical-stage biotechnology company focused on developing novel therapies for immune-mediated diseases, with investigational compounds such as reproxalap and ADX-629, targeting reactive aldehyde species in inflammatory diseases.
Aldeyra Therapeutics (Nasdaq: ALDX) announced promising results from the run-in cohort of its Phase 3 TRANQUILITY trial for reproxalap in dry eye disease. The study involved 23 patients, revealing that reproxalap significantly improved ocular dryness and discomfort compared to the vehicle solution (p = 0.001 and p < 0.0001). The drug was also well-tolerated with no adverse safety findings. Aldeyra plans to begin enrollment for the main cohort in February 2021, with results expected in the second half of 2021. This positions reproxalap as a potential first-line treatment for chronic dry eye disease.
Aldeyra Therapeutics (Nasdaq: ALDX) announced a conference call scheduled for January 7, 2021, at 8:00 a.m. ET to discuss top-line results from the Phase 3 TRANQUILITY trial's run-in cohort for dry eye disease. The main cohort of the trial is set to begin enrollment in February 2021, pending tear RASP analysis. Aldeyra is advancing investigational therapies targeting RASP for immune-mediated diseases, including reproxalap and ADX-629, which are undergoing Phase 3 trials.
Aldeyra Therapeutics (Nasdaq: ALDX) has confirmed the antiviral activity of ADX-1612 against SARS-CoV-2, based on preclinical studies conducted in collaboration with the Max Delbrück Center in Berlin. This HSP90 inhibitor shows both antiviral and anti-inflammatory effects in human cells infected with the virus. With additional studies planned, ADX-1612 may also enhance the efficacy of other antiviral drugs. Aldeyra's research emphasizes its commitment to developing therapies for serious viral infections, alongside its ongoing clinical trials for other compounds targeting immune-mediated diseases.
Aldeyra Therapeutics (Nasdaq: ALDX) has initiated Phase 2 clinical trials for ADX-629, a novel orally administered reactive aldehyde species (RASP) inhibitor targeting COVID-19, atopic asthma, and psoriasis. This follows a successful Phase 1 trial showing no adverse events and reduced RASP levels. The COVID-19 trial will enroll around 30 patients to assess safety and efficacy, the asthma trial will involve 12 patients, and the psoriasis study will include 10 patients. The aim is to broaden the application of ADX-629 beyond ocular diseases.
